A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis.
about
Immune ablation and stem-cell therapy in autoimmune disease. Immunological reconstitution after high-dose immunosuppression and haematopoietic stem-cell transplantationSustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.Collection of hematopoietic stem cells from patients with autoimmune diseases.Stem cell transplantation for treatment of severe autoimmune diseases: current status and future perspectives.Autologous blood stem cell transplantation as therapy for autoimmune diseases.High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesThe role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders.Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review.Hematopoietic stem cell transplantation for severe rheumatoid arthritis.A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune diseaseHaematopoietic stem cell transplantation for autoimmune disorders: the American perspective.Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationStem cell transplantation in autoimmune diseases: an update.The use of stem cells for the treatment of autoimmune diseases.Stem cell transplantation in rheumatoid arthritis.Autologous hematopoietic stem cell transplantation in autoimmune diseases.Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review.Stem cell autograft and allograft in autoimmune diseases.A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation.Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration.Induction of graft-versus-autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP).Multidrug resistance transporter-1 and breast cancer resistance protein protect against ovarian toxicity, and are essential in ovarian physiology.
P2860
Q24791017-6FA82BF0-A007-4B9E-AE67-D6EE515CE050Q33336433-FCD5B9B9-FF97-45EF-B400-15E5084673FBQ33338475-1A788C4C-8935-4CC9-ABE3-741952EEAF4DQ33867000-ECDFEE53-E489-4A57-8F3B-8E852205BAB9Q34157550-5805C2A1-2755-43ED-8240-6965C6634572Q34208626-940A3549-A190-41ED-AD0E-955236C8E2EEQ34500124-8C2F0447-9353-4A5E-AA71-2C8BF71C7AA3Q35071105-16E0EA7C-28AC-41F3-9E27-38DE30891CA0Q35204112-709FEA4C-7AED-4FDA-A617-F83D7BE2F628Q35636989-81D5C2E3-5DA0-41B3-86AA-5EC048C84E17Q35870515-1FA878A1-C312-47C8-8AB2-4045ED4CF850Q36020897-F7F59F19-FF8A-4306-8BBD-7A5E8E19107DQ36309579-A5CF479D-4E39-489A-86F3-FB6DBCBB8E19Q36916687-BF3AD6C3-E971-4950-9275-418B8BA1F54CQ37311046-BDCA43A4-F26E-417A-8D87-BCBB1B741F04Q37810087-7448CA62-2DBA-412F-9849-1444A71BAB47Q38242079-EE7E0152-2805-4FF9-918F-98D228A2F6DFQ38287103-08BB4001-D6F6-452C-80B6-405688228110Q40498732-6A3BBF70-9DE2-4346-9FAB-0CC3370096B8Q41869348-44FB2C66-1E3D-4E8E-83F6-F01D491CF19BQ44538390-5CAD7BB9-1B75-43BE-86F7-55A6C1376462Q46314561-2AD2A302-8A54-4E9F-ABB2-3AB7EE70589CQ48528733-2A3D2756-DED6-40F9-99FD-8506CE2B1832
P2860
A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
A phase I/II dose escalation s ...... , active rheumatoid arthritis.
@en
type
label
A phase I/II dose escalation s ...... , active rheumatoid arthritis.
@en
prefLabel
A phase I/II dose escalation s ...... , active rheumatoid arthritis.
@en
P2093
P2860
P1476
A phase I/II dose escalation s ...... , active rheumatoid arthritis.
@en
P2093
P2860
P304
P356
10.1002/1529-0131(199911)42:11<2286::AID-ANR5>3.0.CO;2-X
P577
1999-11-01T00:00:00Z